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Abstract
Background: The hexapeptide SLIGRL-amide activates protease-activated receptor-2 (PAR-2) and mas-related G
protein-coupled receptor C11 (MRGPRC11), both of which are known to be expressed on populations of sensory
nerves. SLIGRL-amide has recently been reported to inhibit influenza A (IAV) infection in mice independently of
PAR-2 activation, however the explicit roles of MRGPRC11 and sensory nerves in this process are unknown. Thus,
the principal aim of this study was to determine whether SLIGRL-amide-induced inhibition of influenza infection is
mediated by MRGPRC11 and/or by capsaicin-sensitive sensory nerves.
Methods: The inhibitory effect of SLIGRL-amide on IAV infection observed in control mice in vivo was compared to
effects produced in mice that did not express MRGPRC11 (mrgpr-clusterΔ−/− mice) or had impaired sensory nerve
function (induced by chronic pre-treatment with capsaicin). Complementary mechanistic studies using both in vivo
and ex vivo approaches investigated whether the anti-IAV activity of SLIGRL-amide was (1) mimicked by either
activators of MRGPRC11 (BAM8-22) or by activators (acute capsaicin) or selected mediators (substance P, CGRP) of
sensory nerve function, or (2) suppressed by inhibitors of sensory nerve function (e.g. NK1 receptor antagonists).
Results: SLIGRL-amide and BAM8-22 dose-dependently inhibited IAV infection in mrgpr-clusterΔ−/− mice that do not
express MRGPRC11. In addition, SLIGRL-amide and BAM8-22 each inhibited IAV infection in capsaicin-pre-treated
mice that lack functional sensory nerves. Furthermore, the anti-IAV activity of SLIGRL-amide was not mimicked by
the sensory neuropeptides substance P or CGRP, nor blocked by either NK1 (L-703,606, RP67580) and CGRP
receptor (CGRP8-37) antagonists. Direct stimulation of airway sensory nerves through acute exposure to the TRPV1
activator capsaicin also failed to mimic SLIGRL-amide-induced inhibition of IAV infectivity. The anti-IAV activity of
SLIGRL-amide was mimicked by the purinoceptor agonist ATP, a direct activator of mucus secretion from airway
epithelial cells. Additionally, both SLIGRL-amide and ATP stimulated mucus secretion and inhibited IAV infectivity in
mouse isolated tracheal segments.
Conclusions: SLIGRL-amide inhibits IAV infection independently of MRGPRC11 and independently of
capsaicin-sensitive, neuropeptide-releasing sensory nerves, and its secretory action on epithelial cells warrants
further investigation.
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Background
Worldwide, influenza A virus (IAV) infections are esti-
mated to cause up to 5 million cases of severe illness,
and between 250,000 and 500,000 deaths each year [1].
The potentially devastating impact of seasonal influenza
epidemics is lessened through vaccination, which signifi-
cantly reduces the rate of hospitalisation and death from
influenza. Unfortunately, annual vaccination does not
provide protection against irregular influenza pandemics
caused by antigenically novel strains of IAV transmitted
from other animal species. Thus, considerable effort has
been directed towards preventing and treating IAV in-
fection with antiviral agents including the neuraminidase
inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza)
[2, 3]. Despite these efforts, our capacity to control in-
fluenza infection remains threatened due to the rapid
emergence of resistance to oseltamivir and other
conventional antiviral agents such as the adamantanes
[4–6]. Hence, there is an urgent unmet need to identify
new anti-viral drugs to provide a frontline defence to in-
fection, especially in the event of an unpredictable but
inevitable influenza pandemic.
Our laboratory has recently shown that the hexapeptidic
sequence SLIGRL-amide (Ser-Leu-Ile-Gly-Arg-Leu-NH2)
inhibits IAV infection in mice [7]. SLIGRL-amide is a
well-established activator of protease-activated receptor-2
(PAR-2) [8]. However, SLIGRL-amide inhibits IAV infec-
tion independently of PAR-2 as anti-viral effects were pre-
served in PAR2 (−/−) mice [7]. SLIGRL-amide has also
been reported to activate MRGPRC11, a subtype of MAS-
related G protein-coupled receptor (MRGPR) [8–10].
Whether SLIGRL-amide inhibits IAV infection via
MRGPRC11 is currently unknown.
The MRGPR family comprises approximately 40 mem-
bers that are grouped into nine subfamilies (MRGPRA
to –H, and –X), based on sequence similarities. Subfam-
ilies A, B, C, and H exist only in rodents, whereas sub-
family X is specific to primates including humans [10].
Mouse and rat MRGPRC have been found to exhibit
high similarities with human MRGPRX1 in terms of ex-
pression pattern, sequence homology and binding profile
[11–14]. For example, both rodent MRGPRC11 and
human MRGPRX1 are activated by the agonist BAM8-
22. The expression of these receptors is primarily
restricted to the small-diameter nociceptive sensory neu-
rons [11, 12, 15, 16].
Sensory nerves of the respiratory system innervate a
range of important structures, including the airway epi-
thelium, submucosal glands and airway smooth muscle
[17]. The predominant subtype of airway sensory nerve
is the vagal bronchopulmonary C-fibre, whose cell bod-
ies are located within the jugular and nodose ganglia
[18]. Jugular C-fibres are more likely to innervate the
upper airways [19] and to express neuropeptides when
activated [20]. Noxious substances such as the TRPV1
activator capsaicin can activate populations of sensory
nerves and may promote the release of neuropeptides
such as substance P and CGRP via an axonal reflex [21].
Released neuropeptides, via activation of their cognate
neurokinin (NK) and CGRP receptors, can in turn in-
duce a wide range of biological effects, such as increased
cilia beating and mucus secretion [22]. Several compo-
nents of mucus, including surfactants, secretory IgA,
defensins and MUC5B mucin have been reported to ex-
hibit anti-IAV activities [23].
Thus far, the molecular target mediating the anti-IAV
effects of SLIGRL-amide is unknown. The current study
tests the hypotheses that SLIGRL-amide inhibits IAV in-
fection by activating MRGPRC11, and that the antiviral
effects of SLIGRL-amide are mediated by neuropeptides,
which stimulate the secretion of endogenous substances
with anti-IAV activities from mucus-producing airway
cells. If the hypotheses are correct, then SLIGRL-amide
induced anti-IAV effects should be mimicked by activa-
tors of MRGPRC11 (such as BAM8-22) and by exogen-
ous neuropeptides (such as substance P and CGRP), as
well as by other stimuli that directly activate sensory
nerves (TRPV1 activator capsaicin). Furthermore, the
anti-IAV effects of SLIGRL-amide should be reduced in
mice lacking MRGPRC11 (Mrgpr-clusterΔ−/− mice, [8,
24]) and by processes (capsaicin-induced desensitisation)
or agents (neurokinin receptor antagonists) that sup-
press sensory nerve function. In the current study, the
effect of these interventions on SLIGRL-amide-induced
anti-IAV activity was tested using a combination of in
vivo (airway inflammation in IAV-exposed mice) and
novel ex vivo approaches (immunohistochemical staining
for IAV in viable perfused tracheal explants; [7]). Utilisa-
tion of ex vivo approaches also facilitated preliminary in-




All in vivo animal studies were conducted with the ap-
proval of the University of Western Australia Animal
Ethics Committee (approval number RA/3/100/1258)
and strictly adhered to the guidelines stipulated in the
“Australian code for the care and use of animals for
scientific purposes 8th Edition 2013”, published by the
National Health and Medical Research Council of
Australia. In accordance with the National Health and
Medical Research Council of Australia’s National State-
ment on Ethical Conduct in Human Research 2007,
segments of human lung tissue were obtained with in-
formed written consent from patients undergoing
lobectomy at two West Australian hospitals, Sir Charles
Gairdner Hospital and the Mount Hospital. These
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studies were specifically approved by the Sir Charles
Gairdner Hospital Human Research Ethics Committee
(approval number 2011–128), the Mount Hospital Ethics
Committee (approval number EC71.1) and The Univer-
sity of Western Australia Human Ethics Office (approval
numbers RA/4/1/7256 and RA/4/1/7220).
Influenza virus
Mouse-adapted influenza A/PR/8/34 virus was propa-
gated in the allantoic fluid of 9-day old embryonated
chicken eggs (Altona Hatchery, Forrestfield, Australia)
at 37 °C for 3 days, as described previously [25]. Viral
infectivity was assessed using allantois-on-shell titra-
tion and quantitated via hemagglutination assay [26].
The TCID50 of the harvested allantoic fluid was
10-5.8/ml.
In vivo infection of mice with IAV
Unless otherwise stated, male BALB/c mice (specified
pathogen-free) aged 7 to 8 weeks (Animal Resource
Centre, Murdoch, WA) were housed at the University of
Western Australia Animal Care Unit under a 12 h light/
dark cycle and received food and water ad libitum. The
role of MGRPRC11 in SLIGRL-amide-induced anti-IAV
activity was investigated using Mrgpr-clusterΔ−/− and
wild-type mice, generated as previously described [24].
Groups of mice were lightly anaesthetised (methoxyflurane)
and intranasally (i.n.) inoculated with a 20 μl solution con-
taining (a) influenza A/PR/8/34 virus (1:800 dilution of
stock IAV) alone, (b) IAV plus peptide (SLIGRL-amide,
SLIGR-amide, BAM8-22) or (c) 1:800 dilution of allantoic
fluid (vehicle). Mice were killed with an overdose of
pentobarbitone (160 mg/kg i.p. injection) at day 4 post-
inoculation for determination of IAV-induced inflam-
mation using differential cell counting of leukocytes
recovered from bronchoalveolar lavage (BAL) fluid [7].
Bronchoalveolar lavage
BAL was performed by intratracheal instillation of
2.5 ml of cold phosphate-buffered saline (PBS) pH 7.4,
in 0.5 ml volumes via a tracheal cannula. After each in-
stillation, BAL fluid was recovered, pooled and centri-
fuged at 400 × g for 5 mins at 4 °C. Supernatant was
removed and the cell pellet resuspended in PBS + 1.0 %
bovine serum albumin. Total cell counts and viability
were determined by use of a haemocytometer and 0.4 %
trypan blue exclusion. Cytospin preparations of each cell
sample were stained with DIFF-Quik (Thermo Fisher
Scientific, Waltham, MA), and differential cell counts of
macrophages, neutrophils, eosinophils and lymphocytes
were determined by counting 400 cells under a light
microscope using standard morphological criteria.
Capsaicin-induced attenuation of sensory nerve function
in mice
Administration of multiple subcutaneous injections of
capsaicin to anaesthetised mice is an effective means of
impairing sensory nerve function [27–30]. On day one,
mice were anaesthetized (130 mg/kg ketamine and
13 mg/kg xylazine, i.p.) and administered the bronchodi-
lators terbutaline (0.1 mg/kg, i.p.) and theophylline
(10 mg/kg, s.c.). Twenty mins later, mice were injected
subcutaneously with capsaicin (25 mg/kg, s.c.) in the
neck region between the shoulder blades. On days two
and three, the procedure was repeated with an increased
dose of capsaicin (50 mg/kg, s.c) (capsaicin-pretreated).
Mice were left for 10 days before being intranasally inoc-
ulated with IAV ± SLIGRL-amide, as described above.
Control mice received injections of vehicle (1:1:8 vol/
vol/vol of ethanol/Tween 80/saline) (sham-pretreated).
The protocol is shown in Fig. 3a. The effectiveness of
the capsaicin desensitization protocol was determined in
isometric tension recording studies by examining the
capsaicin-induced relaxation responses in mouse isolated
tracheal smooth muscle preparations.
Isometric tension recording studies
As previously demonstrated in our laboratories [31, 32]
isometric tension recording studies can be used to deter-
mine the functionality of the sensory nerves within the
mouse trachea. Groups of mice exposed to either capsa-
icin or saline (sham) mice were euthanased using pento-
barbitone (160 mg/kg, i.p.). Tracheal segments were
excised and suspended under a resting tension of 0.2 g in
organ baths containing 20 ml of Krebs bicarbonate solu-
tion (117 mM NaCl, 5.36 mM KCl, 25 mM NaHCO3,
1.03 mM KH2PO4, 0.57 mM MgSO4.7H2O, 2.5 mM
CaCl2, 11.1 mM D-glucose) maintained at 37 °C and bub-
bled continuously with 5 % CO2 and 95 % O2. Changes in
tension were recorded via a 751mT miniTOBs organ
bath system (DMT, Aarhus, Denmark) connected to a
Powerlab system (ADInstruments Pty Ltd., Castle Hill,
Australia). Tracheal preparations were allowed to equili-
brate for 30 mins and the viability of the tracheal smooth
muscle was determined by cumulative exposure to a sub-
maximal (0.2 μM) and maximal (10 μM) dose of carba-
chol. Tracheal segments were then repeatedly washed and
allowed to rest for 20 mins. Preparations were precon-
tracted using 1 μM carbachol and upon reaching a plateau
level of tension were exposed to a single 20 μM bolus dose
of capsaicin, and tension recordings continued until the
peak response was obtained.
Ex vivo infection of mouse isolated tracheal segments
with IAV
An airway explant perfusion system developed in our la-
boratories was used as a means of investigating the
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effects of selected peptides (SLIGRL-amide, BAM8-22,
substance P, CGRP) on the capacity of IAV to infect and
replicate in murine isolated airways, as previously de-
scribed [7]. Briefly, tracheae harvested from untreated
mice (male BALB/c mice at 7 to 8 weeks of age) were
mounted onto an 18G blunted needle and perfused for
at least half an hour at 37 °C with complete RPMI
(cRPMI) medium at the rate of 100 μL/min. Complete
RPMI (cRPMI) medium consisted of RPMI 1640
medium (Gibco, Life Technologies-Thermo Fisher
Scientific Inc, MA, USA) supplemented with 20 mM
HEPES, 2 mM GlutaMAX™, 2.0 μg/mL amphotericin B,
20 μg/mL gentamycin, and 1 % foetal calf serum (FCS).
Following this equilibration period, the perfusion was
stopped and the tracheal lumen gently flushed first with
0.5 ml of sterile saline, and then air, before being ex-
posed to IAV (1/800 dilution of stock) ± peptides for 15
mins, without perfusion. The lumen of the airway was
then washed with 0.5 mL of sterile saline to remove un-
attached IAV and peptides, and perfused with cRPMI
(100 μL/min at 37 °C) for 48 h. Airway segments were
removed from the needle and fixed in 2 % paraformalde-
hyde (containing 0.2 % picric acid) in PBS (pH 7.4), for
48 h at 4 °C. Tissues were dehydrated (starting from
50 % ethanol) and processed to paraffin wax on a stand-
ard 15 h cycle in a Leica ASP200S automated tissue pro-
cessor (Wetzlar, Germany).
Isolated airways from human lung
The anti-IAV activity of SLIGRL-amide was also exam-
ined in small airway segments obtained from humans.
Macroscopically normal samples of lung were obtained
from patients undergoing lung surgery, usually for lung
cancer. Segments of small airways (1–2 mm internal
diameter) were dissected free from surrounding lung
tissue and mounted onto the airway explant perfusion
system. Perfused airways were exposed to IAV ±
SLIGRL-amide, as outlined above for mouse studies.
Immunohistochemistry and imaging
The presence of immunoreactive IAV in isolated trachea
of IAV-exposed mice was visualised using standard immu-
nohistochemical procedures, as previously reported [7].
Briefly, 5 μM wax sections were dewaxed, rehydrated and
permeablized with 1 % Triton X-100 for 15 mins. Tissues
were then blocked with 20 % normal rabbit serum or 3 %
fish skin gelatin for 1 h and further exposed to
avidin/biotin blocking as per manufacturer’s instruc-
tions (Avidin/Biotin Blocking Kit; Vector Laboratories,
Burlingame, CA). Goat anti-influenza A polyclonal
antibody, 1/1000 dilution (5 μg/ml) (Millipore Corpor-
ation, Billerica, MA); mouse anti-influenza A monoclonal
antibody, 1/500 dilution (14.5 μg/ml) (Abcam, Cambridge,
ENG); normal goat IgG isotype control or normal mouse
serum were applied to sections and incubated overnight at
4 °C. After overnight incubation, sections were thoroughly
washed in Tris-buffered saline (TBS) for one hour and en-
dogenous peroxidase was quenched with 0.3 % H2O2 in
TBS for 15 mins. The sections were then exposed to bio-
tinylated rabbit anti-goat secondary IgG, 1/200 dilution
(Vector Elite ABC kit; Vector Laboratories) or biotinylated
rabbit anti-mouse IgG F(ab')2, 1/200 dilution (3.65 μg/ml)
(Dako, Denmark) for 45 mins, followed by avidin-biotin-
horseradish-peroxidase complex (Vector Elite ABC kit;
Vector Laboratories) for 45 mins. The bound complex
was visualised with diaminobenzidine (DAB, 0.4 mg/ml).
Sections were counterstained with Mayers haematoxylin
and blued with Scotts Tap Water Substitute, washed and
dehydrated through graded alcohols to xylene, then cover-
slipped with Depex mounting medium. Digital images
were acquired on an Aperio ScanScope XT digital slide
scanner (Leica (Aperio) Technologies, Vista, CA). Images
represent at least three animals per treatment.
Visualisation of immunoreactive IAV in human iso-
lated bronchioles was achieved following the same
protocol as for mouse tissue (described above) but with
the following modifications - the diluent for both the
primary and secondary antibodies was 3 % fish skin gel-
atin (FSG) (Sigma-Aldrich, St. Louis, MO) in 50 mM
Tris + 0.5 M NaCl + 0.01 % Triton-X-100 . The blocking
solution was 0.3 M glycine in 3 % FSG, and the wash
buffer (50 mM Tris + 0.5 M NaCl + 0.01 % Triton-X-
100) contained 0.3 M glycine. Avidin/Biotin blocking
was not performed. All antibody concentrations, incuba-
tion and washing times, and visualisation with DAB
remained the same.
Quantitative analysis of immunoreactive IAV in mouse
tracheal epithelium
Digital images of sections stained for immunoreactive
IAV (and visualised with diaminobenzidine), were
generated using a ScanScope XT digital slide scanner
(Leica (Aperio) Technologies, Vista, CA) and analysed
using ImageScope v11.1.2. The Positive Pixel Count
v9 algorithm (Aperio Technologies) was applied with
input parameters of - colour saturation threshold
(0.01), hue value (0.1) and intensity ranges for weak
positive (175–220), positive (100–175) and strong
positive (0–175) pixels. These parameters were ap-
plied to an algorithm able to quantify diaminobenzi-
dine positive sites of IAV expression, which were
stained dark brown, as “strong positive pixels”. The
number of strong positive pixels (SPP) in the epithe-
lium was counted by the algorithm and expressed as
a percentage of the total pixels within the epithelial
layer (%SPP). %SPP was calculated for each tracheal
section and provided a means of quantifying changes
in levels of IAV staining.
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Attenuation of sensory nerve function in mouse isolated
tracheal segments
To investigate whether capsaicin-induced inhibition of
sensory nerve function blocks the anti-IAV effects of
SLIGRL-amide in vitro, mouse tracheas from naïve mice
were connected to the airway explant perfusion system
and then exposed to capsaicin (20 μM) for 10 mins.
Capsaicin-exposed preparations were washed and per-
fused with cRPMI for a further 10 mins prior to a stand-
ard 15 min exposure to IAV ± SLIGRL-amide. Tracheal
segments were washed and perfused for 48 h with
cRPMI, and then processed to determine levels of im-
munohistochemical staining for IAV. Complementary
isometric tension recording studies were performed to
confirm that in vitro capsaicin pre-treatment inhibited
TRPV1-mediated activation of airway sensory nerves.
Mucin secretion studies
The capacity of selected compounds to stimulate mucin
release from epithelial stores of mucin was determined
using the airway explant perfusion system. Following a
24 h period of perfusion with cRPMI, mouse isolated
tracheal segments were exposed for 15 mins to SLIGRL-
amide (200 μM), BAM8-22 (25 μM), substance P
(1 μM), CGRP (1 μM) or to the known mucin secreta-
gogue ATP (100 μM), or to saline. Tissues were then
fixed in 2 % paraformaldehyde (containing 0.2 % picric
acid) in PBS (pH 7.4), for 48 h at 4 °C, processed to
paraffin wax and 5 μm sections stained with Alcian
Blue-Periodic acid-Schiff ’s reagent (AB-PAS) to demon-
strate the presence of mucins (the chief glycoprotein
constituent of mucus) in the epithelial layer. The chosen
concentration and period of exposure to ATP were
based on those employed in mucin release studies con-
ducted in mice [33, 34].
Quantitative analysis of AB-PAS staining in mouse
tracheal epithelium
Digital images of AB-PAS stained sections were gener-
ated using a ScanScope XT digital slide scanner (Leica
(Aperio) Technologies, Vista, CA) and analysed using
ImageScope v11.1.2 and the Positive Pixel Count v9 al-
gorithm (Aperio Technologies). Input parameters (color
saturation threshold (0.04), hue value (0.1) and intensity
ranges for weak positive (188–238), positive (176–188)
and strong positive (0–176) pixels) were defined to gen-
erate an algorithm able to quantify AB-PAS-positive
stores of mucin stained bright pink (as “strong positive
pixels”). The number of strong positive pixels (SPP) in
the epithelium was counted by the algorithm and
expressed as a percentage of the total pixels within the
epithelial layer (%SPP). %SPP was calculated for each
tracheal section and provided a means of quantifying
changes in levels of mucin staining.
Materials
SLIGRL-amide, BAM8-22, SLIGR-amide and CGRP8-37
were supplied by Auspep (Melbourne, Australia). Stock
solutions were prepared in sterile high-purity water with
subsequent dilutions made in sterile saline. The concen-
tration, purity, and composition of the peptides were de-
termined by high-performance liquid chromatography,
mass spectrometry, and quantitative amino acid analysis.
Carbachol (carbamylcholine chloride), ATP, indometh-
acin, atropine, propranolol, terbutaline, theophylline and
L-703,606 were purchased from Sigma–Aldrich (St. Louis,
MO), whilst RP-67580 ((3aR,7aR)-Octahydro-2-[1-imino-2-
(2-methoxy-phenyl)ethyl]-7,7-diphenyl-4H-isoindol), sub-
stance P, CGRP and L-733,060 were obtained from Tocris
Bioscience (Ellisville, MO). Sodium pentobarbitone was
supplied by Virbac Australia (Peakhurst, NSW), methoxy-
flurane by Medical Developments International Ltd
(Springvale, Australia) and Schiff reagent by Australian
Biostain (Vic, Australia).
Statistical analysis
Unless otherwise stated, grouped data are expressed as
mean ± SEM. Statistical comparisons between groups
were made using one-way ANOVA with post-hoc testing
(Holm procedure for all pairwise comparisons or
Dunnett’s test for comparisons to single control) using
InVivoStat software. Differences between groups were
considered statistically significant at p <0.05.
Results
Effect of selected peptides on IAV infection in mice in
vivo
As shown in Fig. 1, BAL fluid recovered from the lungs
of sham-inoculated mice (No IAV) consistently con-
tained approximately 0.15 million cells, of which 99 %
were macrophages. In contrast, intranasal inoculation of
IAV caused a marked influx of inflammatory cells into
the lungs of mice, and by day 4 post-inoculation, the
total BAL cell number was increased by approximately
10-fold, primarily due to a time-dependent influx of
macrophages and neutrophils [7]. As expected, SLIGRL-
amide (activator of PAR-2 and MRGPRC11; [8]) dose-
dependently inhibited the IAV-induced increase in BAL
leukocyte number (Fig. 1). BAM8-22, which activates
MRGPRC11 but not PAR-2 [8]) also inhibited IAV-
induced increases in BAL leukocyte number, and was
approximately 10-times more potent than SLIGRL-
amide (Fig. 1). In contrast, SLIGR-amide (activator of
PAR-2 but not MRGPRC11; [8, 35]) did not inhibit IAV-
induced increases in total BAL cell number at the high-
est dose tested (40 nmol/mouse) (Fig. 1). On face value,
these data support the postulate that MRGPRC11 medi-
ates the anti-IAV activities of SLGRL-amide and BAM8-
22. However caution is required in this interpretation as
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SLIGRL-amide and BAM8-22 may not specifically acti-
vate MRGPRC11, and other receptors may be involved
in mediating their anti-IAV effects.
Anti-IAV activity of SLIGRL-amide and BAM8-22 in Mrgpr-
clusterΔ−/− and wild-type mice
To definitively evaluate the role of MRGPRC11 in the
anti-IAV activities of SLIGRL-amide and BAM8-22,
studies were conducted using Mrgpr-clusterΔ−/− mice
that do not express MRCPRC11 [8, 24]. Intranasal in-
oculation of mice (Mrgpr-clusterΔ−/− and wild-type) with
IAV (in the absence of peptides) was associated with a
marked increase in total BAL cell number on day 4
post-inoculation (Fig. 2). As expected, both SLIGRL-
amide (6 and 30 nmol/mouse) and BAM8-22 (0.5 and
2 nmol/mouse) inhibited the IAV-induced increase in
total BAL cell number in wild-type mice [24] (Fig. 2a
and 2c). However, contrary to the hypothesis that
MRGPRC11 mediates the anti-IAV effects of SLIGRL-
amide and BAM8-22, doses of these peptides that inhib-
ited IAV-induced increases in total BAL cell number in
BALB/c mice (Fig. 1a) and wild-type mice (Fig. 2), also
exhibited anti-IAV activity in Mrgpr-clusterΔ−/− mice
(Fig. 2b and 2d). These findings provide strong evidence
that the anti-IAV activities of either SLIGRL-amide or
BAM8-22 are not mediated by MRGPRC11.
Role of sensory nerves in SLIGRL-amide-induced anti-IAV
activity
Further studies were completed to evaluate the possibil-
ity that the anti-IAV activity of SLIGRL-amide was
mediated by capsaicin-sensitive, neuropeptide-releasing
airway sensory nerves. In these studies, the activity of
SLIGRL-amide was investigated in mice in which sen-
sory nerve function had been attenuated by either (1)
chronic exposure to capsaicin or (2) administration of a
neurokinin receptor antagonist.
Repeated daily exposure to capsaicin has previously
been reported to cause chemical ablation of sensory
nerves in mice [27, 29, 36–38]. In our studies, anaesthe-
tized mice were exposed to capsaicin on 3 consecutive
days (see Fig. 3a for protocol), and confirmation of the
effectiveness of this in vivo protocol to induce airway
sensory nerve dysfunction was obtained from isometric
tension recording experiments (Fig. 3b and 3c, lower
panels). Tracheal smooth muscle segments from
capsaicin-pre-treated mice did not relax in response to
capsaicin, compared to the large relaxation response ob-
tained in sham-pre-treated (no capsaicin) mice (Fig. 3b
and 3c), consistent with sensory nerve dysfunction.
Inoculation with IAV on day 13 of the protocol pro-
duced similar increases in BAL leukocytes in sham and
capsaicin-pretreated mice (Fig. 3d and 3e). Moreover,
IAV-induced increases in BAL leukocytes were inhibited
by SLIGRL-amide in both sham (Fig. 3d) and capsaicin-
pretreated mice (Fig. 3e). These findings do not support
a role for classic TRPV1-expressing, sensory C-fibres in
SLIGRL-amide-induced inhibition of IAV infectivity.
Some populations of activated airway sensory nerves
release neuropeptides such as the tachykinin substance
P, which transmits responses via activation of neurokinin
(NK) receptors. Consistent with this, NK1 receptor


































Fig. 1 Measurement of relative anti-IAV activities of SLIGRL-amide, BAM8-22 and SLIGR in mice by counting leukocytes recovered from BAL fluid.
Mice were anaesthetised and intranasally inoculated with IAV in the presence or absence of selected doses of peptides. Four days later, BAL
leukocyte numbers were determined for each mouse. Shown are mean ± s.e.mean values from 4–10 mice/group. *, indicates P < 0.05 compared
to respective IAV + saline control (one-way ANOVA)
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antagonists inhibit substance P-induced effects on micro-
vascular leakage, mucus secretion and bronchomotor tone
in the airways (see [39]). In the current study, administra-
tion of the NK1 receptor antagonist L-703,606 (8.5 mg/kg;
[40, 41]) did not block the capacity of SLIGRL-amide to
inhibit IAV-induced increases in total BAL cell number in
mice (Fig. 4), indicating that the actions of SLIGRL-amide
were not mediated via activation of the sensory nerve –
substance P – NK1 receptor axis.
Effect of SLIGRL-amide and BAM8-22 on IAV infectivity in
mouse isolated trachea ex vivo
Our laboratories have previously demonstrated that the
antiviral activity of SLIGRL-amide observed in intact
mice can be replicated in mouse isolated trachea ex vivo
[7]. The novel ex vivo perfused tracheal system preserves
tissue viability, architecture and microenvironment of
the airways, and enables the study of the cellular mecha-
nisms through which SLIGRL-amide inhibits IAV virus
infection. Furthermore, this ex vivo perfusion system can
be adapted to airways of other non-murine species, in-
cluding human airways. In ex vivo studies, the levels of
immunoreactive staining for IAV within the airway epi-
thelium is the primary endpoint used to indicate IAV in-
fectivity [7]. Extensive immunoreactive staining for IAV
is indicative that the virus has proceeded through the se-
quential processes of viral attachment, endocytosis and
replication. In the current study, a brief 15 min exposure
of mouse isolated trachea to IAV resulted in the subse-
quent propagation of IAV within the epithelium over the
ensuing 48 h, as revealed by the presence of high levels
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Fig. 2 Measurement of anti-IAV activities of SLIGRL-amide and BAM8-22 in wild-type and Mrgpr-clusterΔ−/− mice by counting BAL leukocytes.
Wild-type (a, c) and Mrgpr-clusterΔ−/− (b, d) mice were anaesthetised and intranasally inoculated with IAV and selected doses of SLIGRL-amide
(a, b) or BAM8-22 (c, d). Four days later, BAL was performed on each mouse and the total numbers of leukocytes recovered was determined.
Shown are mean ± s.e.mean of 3 mice per group. *, indicates P <0.05, compared to respective IAV + saline control (one-way ANOVA)
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stark contrast, mouse tracheal segments exposed to
SLIGRL-amide and BAM8-22 during the 15 min expos-
ure period to IAV revealed negligible levels of immuno-
histochemical staining for IAV (Fig. 5a and 5b),
indicating that IAV infectivity had been impaired by
these peptides. Thus, as well as inhibiting IAV-induced
increases in total BAL cell number in vivo (Fig. 1),
SLIGRL-amide and BAM8-22, also inhibited IAV infect-
ivity in mouse isolated tracheal segments (Fig. 5).
Effect of sensory nerve activation on IAV infectivity
Consistent with in vivo studies, the evidence obtained
from studies using isolated mouse tracheal segments did
not support the postulate that the anti-IAV effects of
SLIGRL-amide were mediated by activation of capsaicin-
sensitive, neuropeptide-releasing sensory nerves. For
example, the acute and direct activation of sensory nerves
caused by a single 15 min exposure to capsaicin failed to
inhibit IAV infectivity (Fig. 6a). Similarly, the exogenous
application of selected sensory neuropeptides known to be
released locally from activated sensory nerves (substance
P or CGRP at 1 μM), did not mimic the anti-IAV effects
of SLIGRL-amide (Fig. 6b and 6c). Furthermore, neither
an NK1 receptor antagonist (RP67580, 20 μM) nor a
CGRP receptor antagonist (CGRP8-37, 10 μM) blocked
SLIGRL-amide-induced inhibition of IAV infectivity in
mouse tracheal segments (Fig. 6b and 6c).
Effect of SLIGRL-amide and ATP on release of epithelial
mucin stores from mouse isolated tracheal segments
Additional experiments were conducted to investigate
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Fig. 3 Effect of sensory nerve dysfunction caused by in vivo capsaicin treatment on the anti-IAV activity of SLIGRL-amide in mice. a Protocol for
capsaicin-induced dysfunction of sensory nerves. On 3 consecutive days, groups of mice were anaesthetised and injected subcutaneously with
capsaicin or vehicle (Sham). Ten days later, mice were anaesthetised and intranasally inoculated with IAV in the presence or absence of SLIGRL-
amide. A further four days later, BAL was performed on each euthanased mouse and the total numbers of leukocytes recovered was determined.
b & c Isometric tension recordings performed on day 13 show that capsaicin pretreatment (using the protocol in a) abolishes the characteristic
relaxant response to capsaicin (10 μM), indicative of sensory nerve dysfunction. d & e Total BAL leukocyte numbers recovered from IAV-inoculated mice
that had been sham-pretreated (d) or pretreated with capsaicin to induce sensory nerve dysfunction. Shown are mean ± s.e.mean of 3–7 mice per
group. *, indicates P <0.05, compared to respective IAV + saline control (one-way ANOVA)
Chang et al. Respiratory Research  (2016) 17:62 Page 8 of 14
of substances with anti-IAV activity directly from the air-
way epithelium. Consistent with this, exposure of tra-
cheal segments to SLIGRL-amide was associated with a
marked reduction in the levels of AB-PAS staining
within the tracheal epithelium, indicative of mucin
release (left-hand panels of Fig. 7a and 7b). Levels of
AB-PAS staining were also reduced by the established
secretagogue ATP and by BAM8-22, but not by either
substance P or CGRP (Fig. 7b). Of particular interest,
ATP also inhibited IAV infectivity in mouse isolated tra-
cheal segments (right hand panels of Fig. 7a), similar to
the effect produced by SLIGRL-amide.
Effect of SLIGRL-amide on IAV infectivity in airways of
human isolated airways
As indicated above, an advantage of the ex vivo perfused
airway system is that it can be readily adapted to enable
the study of human airways. A 15 min exposure of hu-
man isolated bronchioles to IAV, followed by two days
of perfusion with IAV-free cRPMI medium was associ-
ated with the development of high levels of staining for
immunoreactive IAV within the epithelium, consistent
with the replication of IAV (Fig. 8a). Co-incubation of
IAV with SLIGRL-amide during the initial 15 min expos-
ure period was associated with significantly suppressed
the levels of epithelial IAV immunoreactivity in ex vivo
segments of human bronchioles two days later (P = 0.05;
Fig. 8b), consistent with findings obtained from in vivo
and ex vivo studies using mice.
Discussion
SLIGRL-amide activates murine PAR-2, and has been
used for over twenty years to evaluate the role of PAR-2
activation in physiological and pathological processes
[42–45]. SLIGRL-amide has also recently been shown to
activate MRGPRC11, a G protein-coupled receptor
expressed exclusively on sensory nerves [8], and to in-
hibit IAV infection in mice that lack PAR-2 [7]. The
current study sought to determine whether the antiviral





























Fig. 4 Effect of in vivo administration of an NK1 receptor antagonist
on the anti-IAV activity of SLIGRL-amide in mice. Groups of mice
were injected with L-703,606 (8.5 mg/kg, i.p.) or vehicle (control),
and 30 mins later intranasally inoculated with IAV in the presence or
absence (saline) of SLIGRL-amide. A further four days later, BAL was
performed on each euthanased mouse and the total numbers of
leukocytes recovered was determined, as shown (mean ± s.e.mean
of 4–5 mice per group). *, indicates P <0.05 compared to respective

































Fig. 5 Semiquantitative measurement of anti-IAV activities
of SLIGRL-amide and BAM8-22 in mouse isolated tracheal
segments by immunohistochemical staining of IAV nucleoprotein.
a Immunohistochemical staining for IAV nucleoprotein in mouse
tracheal sections. Mouse tracheal segments were mounted onto an
airway explant perfusion system and incubated for 15 mins with IAV in
the presence or absence of SLIGRL-amide or BAM8-22. Some tracheal
segments were exposed to dilute allantoic fluid instead of IAV (No IAV).
After 48 h of perfusion with media, segments were fixed, paraffin-
embedded, sectioned and immunohistochemically stained for IAV.
Shown are representative images from at least 3 experiments. Bar =
50 μm. b Levels of staining for immunoreactive-IAV in the epithelium
of perfused trachea exposed to IAV in the absence (n = 29 trachea) or
presence of SLIGRL-amide (n = 8 trachea) or BAM8-22 (n = 4 trachea).
Some tracheal segments were exposed to dilute allantoic fluid instead
of IAV (No IAV; n= 3 trachea). Shown are mean levels of immunoreactive
IAV staining (and standard error of the mean), expressed as % of strong
positive pixels, as outlined in the Methods section. *, indicates P<0.05,
compared to IAV + saline control (one-way ANOVA)
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activation of MRGPRC11 and/or sensory nerves, and to
determine whether SLIGRL-amide also inhibited IAV in-
fectivity in human airways.
In the current study, IAV infectivity in intact mice and
in mouse isolated tracheal segments was inhibited by
BAM8-22, an established activator of MRGPRC11 [8, 13].
Indeed, the observed 10-fold greater anti-IAV potency of
BAM8-22 compared to SLIGRL-amide in mice was con-
sistent with an action on MRGPRC11 [8, 10]. However,
both SLIGRL-amide and BAM8-22 were effective in pre-
venting IAV infection in Mrgpr-clusterΔ−/− mice that do
not express MRGPRC11 [8]. These latter studies con-
ducted in Mrgpr-clusterΔ−/− mice provide compelling evi-
dence that the anti-IAV activities of SLIGRL-amide and
BAM8-22 were mediated independently of MRGPRC11.
Additional pharmacologic studies were then undertaken
to determine whether the anti-IAV properties of SLIGRL-
amide and BAM8-22 involved activation of a popula-
tion of capsaicin-sensitive, peptidergic airway sensory
nerves.
We hypothesised that if SLIGRL-amide inhibits IAV
infection via activation of capsaicin-sensitive sensory
nerves, then the anti-IAV activity of SLIGRL-amide
should be suppressed following the chemical ablation of
sensory nerves by repeated exposure of rodents to capsa-
icin [27, 29, 36–38]. However, the anti-IAV effects pro-
duced by SLIGRL-amide were preserved in mice that
had been exposed to capsaicin on three consecutive days
10 days prior to inoculation with IAV, despite tracheal
preparations obtained from these mice failing to produce
a characteristic relaxation response to capsaicin [32].
Consistent with the findings of these in vivo studies, in
vitro pre-treatment of mouse isolated tracheal segments
to capsaicin rendered them unresponsive to subsequent
challenges to capsaicin, but not to the anti-IAV actions
of SLIGRL-amide. Furthermore, although NK1 receptors
have previously been implicated in SLIGRL-amide-
induced actions in mouse trachea [46] and small intes-
tine [47], neither NK1 nor CGRP receptor antagonists
blocked the anti-IAV activities of SLIGRL-amide, in vivo
or ex vivo. Thus, our data do not support the explicit hy-
pothesis that SLIGRL-amide inhibits IAV via activation
of capsaicin-sensitive sensory nerves, or via the actions
of the neuropeptides substance P or CGRP.
In a complementary series of experiments, we tested the
postulate that if SLIGRL-amide inhibits IAV infection via
activation of sensory nerves and local release of neuropep-
tides, then other agents that stimulate sensory nerves
would mimic the anti-IAV actions of SLIGRL-amide. Cap-
saicin directly activates sensory nerve C-fibres via stimula-
tion of the highly expressed TRPV1 calcium ion channel.
However, exposing mouse isolated tracheal segments to
capsaicin together with IAV did not mimic the anti-IAV
























































































Fig. 6 Effect of neuropeptide receptor antagonists on the anti-IAV
activities of SLIGRL-amide in mouse isolated tracheal segments by
immunohistochemical staining of IAV nucleoprotein. Levels of
staining for immunoreactive-IAV in the epithelium of perfused
trachea exposed to IAV in the absence or presence of single acute
dose of (a) capsaicin (10 μM), (b) substance P (1 μM) or (c) CGRP
(1 μM) (n = 3-15 trachea). Also shown are the effects produced by an
NK1 receptor antagonist (20 μM RP67580; b) and a CGRP receptor
antagonist (10 μM CGRP8-37; c) on the anti-IAV activity of SLIGRL-
amide. Shown are mean levels of immunoreactive IAV staining (and
standard error of the mean), expressed as % of strong positive pixels,
as outlined in the Methods section. *, indicates P <0.05, compared to
respective IAV + saline control (one-way ANOVA)
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capsaicin was used at a concentration (10 μM) that in-
duced large relaxation responses in mouse isolated tra-
cheal preparations [32]. These responses were blocked by
a TRPV1 antagonist (capsazepine) and an NK1 receptor
antagonist (L-733060), consistent with sensory nerve acti-
vation [32]. In addition, if the anti-IAV effects of SLIGRL-
amide were mediated via the actions of substance P and/
or CGRP released from activated sensory nerves, then the
exogenous application of these neuropeptides should also
inhibit IAV infectivity. However, neither substance P nor
CGRP, at concentrations known to induce maximal recep-
tor activation, inhibited IAV infectivity in mouse isolated
tracheal preparations. Together, these findings do not sup-
port the postulate that activation of capsaicin-sensitive,
neuropeptide-releasing sensory nerves at the time of IAV
exposure significantly inhibits IAV infectivity in the epi-
thelium of mouse isolated trachea.
Sensory nerve C fibre function has been reported to
influence the response of the host to respiratory tract in-































Fig. 7 Comparative effects of SLIGRL-amide and ATP on promoting mucin release and inhibiting IAV infectivity in mouse isolated tracheal segments.
a Effect of SLIGRL-amide and the purinoceptor agonist ATP on levels of AB-PAS (left-hand panels) and IAV (right-hand panels) staining in sections of
mouse trachea. In AB-PAS experiments, mouse isolated tracheal segments were mounted onto the explant perfusion system and pre-perfused for
24 h, and then incubated for 15 min with saline, SLIGRL-amide or ATP. Segments were fixed, paraffin-embedded, sectioned and stained with AB-PAS.
In IAV immunohistochemical staining experiments, tracheal segments were mounted onto the explant perfusion system and incubated for 15 min
with IAV in the presence of absence of saline, SLIGRL-amide or ATP. After two days of perfusion with media, segments were fixed, paraffin-embedded,
sectioned and immunostained for IAV. Shown are representative images from at least 3 experiments. Bar = 50 μm. b Residual levels of AB-PAS staining,
expressed as %SPP (strong positive pixels), within the epithelium of mouse isolated tracheal segments following a 15 min exposure to saline (control,
white fill) or selected compounds (black fill) (n = 4-8 tracheal segments per group). Luminal exposure to SLIGRL-amide, BAM8-22 and ATP, but not
CGRP or substance P (SubP), stimulated a reduction in epithelial AB-PAS staining, consistent with mucin secretion. *, P <0.05, compared to vehicle
(one-way ANOVA, Dunnett’s posthoc test)
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environmental toxicants [27, 37, 38, 48–50], however lit-
tle is known of the consequence of sensory nerve activa-
tion or sensory nerve dysfunction on influenza infection.
In the current study, stimulation of sensory nerves with
capsaicin during an initial period of IAV exposure did
not prevent the subsequent propagation of IAV within
the epithelium of mouse isolated airways. These findings
indicate that local release of neuropeptides following
sensory nerve activation does not markedly impact on
the capacity of IAV to enter and replicate in airway epi-
thelial cells.
The current study has established that SLIGRL-amide
inhibits IAV infectivity in vivo and ex vivo via mecha-
nisms that are independent of MRGPRC11 and of
capsaicin-sensitive sensory nerves, and also independent
of the sensory neuropeptides substance P and CGRP and
their receptors. However, it is important to note that
vagal bronchopulmonary C-fibers in the mouse are het-
erogeneous – a substantial fraction of C-fiber afferent
nerves in the mouse respiratory system are capsaicin-
insensitive [51], and that a fraction of capsaicin-sensitive
C-fibers are non-peptidergic [20]. Thus, we cannot ex-
clude the possibility that SLIGRL-amide may exert its
antiviral activities through actions on sub-populations of
capsaicin-insensitive, nonpeptidergic neurons. Neverthe-
less, the current investigation builds on our previous
studies that demonstrate SLIGRL-amide does not inhibit
IAV infectivity via PAR-2, by direct antiviral or by im-
munomodulatory processes [7]. Of particular interest,
the current study has shown that the anti-IAV effects of
SLIGRL-amide observed in murine airways extend to
human airways, although further studies are required to
identify its specific molecular target.
SLIGRL-amide and related peptides have been re-
ported to directly stimulate secretory pathways in the
airways [46, 52–54]. Importantly, components of airway
secretions, including the mucin MUC5AC exert protect-
ive roles against influenza A virus [55]. Thus, the release
of endogenous antiviral substances in mucus may con-
tribute to the anti-IAV activity of SLIGRL-amide. In the
current study, SLIGRL-amide promoted the release of
































Fig. 8 Semiquantitative measurement of anti-IAV activities of SLIGRL-
amide in human isolated bronchiolar segments by immunohistochemical
staining of IAV nucleoprotein. a Immunohistochemical staining of IAV in
sections of human isolated bronchiolar segments exposed to IAV in the
absence (upper image) or presence of SLIGRL-amide (lower image), for
15 min. After 48 h of perfusion with media, segments were fixed, paraffin-
embedded, sectioned and immunohistochemically stained for IAV. Bar =
50 μm. b Levels of staining for immunoreactive IAV nucleoprotein in the
bronchiolar epithelium of perfused human airways exposed to saline or
SLIGRL-amide. Shown are representative images from at least 4–9
experiments using airways from different donors. *, indicates P <0.05,
compared to IAV + saline control (one-way ANOVA)
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determined from microscopic imaging of AB-PAS-
stained airway sections. The purinergic receptor agonist
ATP, an established key secretagogue for airway epithe-
lium [56–58], also promoted the release of intracellular
mucins from mouse isolated tracheal epithelium, and
moreover, inhibited IAV infectivity. These findings pro-
vide preliminary evidence that SLIGRL-amide may in-
hibit IAV infectivity by stimulating the secretion of
endogenous substances with anti-IAV activity. Neverthe-
less, it remains to be determined whether the anti-IAV
activity of SLIGRL-amide involves the secretion of sialic
acid-rich mucins [55], or other anti-IAV molecules such
as cationic host defence peptides (β-defensins, cathelici-
dins) [59] or phospholipids such as palmitoyl-oleoyl-
phosphatidylglycerol (POPG) [60].
Conclusion
The current study using a combination of in vivo and ex
vivo approaches provides compelling evidence that the
anti-IAV activity of SLIGRL-amide in murine airways
occurs independently of the sensory nerve receptor
MRGPRC11 and of neuropeptide release from TRPV1-
expressing sensory nerves. Preliminary data show that
both SLIGRL-amide and ATP release airway secretions
and inhibit IAV infection, raising the possibility that
SLIGRL-amide inhibits IAV infectivity via the release of
antiviral substances from the airway epithelium.
Additional release and intervention studies, particularly
in human airways, will provide invaluable insight into
the molecular target and cellular signalling processes
through which SLIGRL-amide inhibits IAV infectivity.
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